Kornimate/medical-research-clean huggingface dataset:
assessment of oral health knowledge, attitude and behavior of adult patients in egypt

Conditions: Oral Health Knowledge, Attitude and Practice Among Patients

Summary: oral health is a significant contributor to public health and is classified by the world health organization (who) as a major global health concern. notably, one in two adults suffer from dental decay ,with oral diseases ranking among the most prevalent non-communicable disease (ncds) . thus, public health programs focus on modifying lifestyle factors for prevention rather than treatment. in developed countries , public health programs have successfully improved oral health through dietary and lifestyle modifications, as well as fluoride use . furthermore, oral health professionals have a crucial in role in influencing the behaviors of their patients and preventing oral diseases .therefore, enhancing oral health knowledge is essential for positive health behaviors and hence better oral health outcomes .


Eligibility criteria:
inclusion criteria: * adult patients attending the diagnostic center in newgiza university * 18 years or older exclusion criteria * patients who refuse to consent to participate in the survey
fluid responsiveness predicted by a stepwise peep elevation recruitment maneuver in mechanically ventilated patients

Conditions: Mechanical Ventilation; Respiration, Artificial

Summary: hemodynamic and fluid optimization during perioperative period can reduce postoperative morbidity. the assessment of preload and determination of whether the patient is fluid responsive is still challenging. static preload indices such as central venous pressure are not accurate to assess fluid responsiveness contrary to dynamic preload indices such as pulse pressure variation (ppv) and stroke volume (sv) variation. however, such indices suffer from several limitations and should be used under strict conditions. alternative dynamic methods such as lung recruitment maneuvers (lrm) have been developed lrm can be used to reopen or prevent collapsed lung under mechanical ventilation so as to decrease respiratory complications. lrm induces a transient increase in intra-thoracic pressure and decreases in venous return, leading to a decrease in left ventricular end-diastolic area and stroke volume. several studies have shown that the peep-induced decrease in stroke volume is related to pre-existing preload responsiveness. few studies have also shown that lrm can represent a functional test to predict fluid responsiveness. however, monitoring stroke volume during lrm to assess fluid responsiveness is costly, and cardiac output devices may not be reliable. in this context, central venous pressure (cvp) or systemic arterial parameters monitoring are easily accessible and inexpensive during major surgery.

the aims of the current study were 1. to assess the ability of a lrm with a stepwise increase of peep to predict fluid responsiveness in mechanically ventilated patients, 2. to identify the best criteria for fluid responsiveness prediction between variations of systolic aortic pressure (sap), mean arterial pressure (map), diastolic aortic pressure (dap), pulse pressure (pp) and central venous pressure (cvp), 3. to compare the ability of these criteria with pulse pressure variation (ppv) to predict fluid responsiveness

Eligibility criteria:
inclusion criteria: * needing invasive arterial blood pressure and pulse contour analysis (picco system) for cardiac output measurement, * central venous pressure monitoring, * using of protective mechanical ventilation * indication for fluid expansion * admitted in the intensive care unit of chu of st etienne exclusion criteria: * right ventricular dysfunction * significant valvulopathy, * ejection fraction less than 50%, * arrhythmia * contraindication to lrms

Keywords: mechanical ventilation lung recruitment maneuver central venous pressure pulse pressure stroke volume fluid responsiveness
a randomized controlled study of rolapitant for the prevention of nausea and vomiting following surgery (study p04937am1)(completed)

Conditions: Postoperative Nausea and Vomiting

Summary: this is a multicenter, randomized, controlled study in women who are having elective open abdominal surgery with general anesthesia and who are expected to need patient-controlled analgesia (pca) after surgery. the primary objective is to assess the effect of rolapitant in the prevention of postoperative nausea and vomiting as measured by the prevention of vomiting in the first 24 hours after surgery. participation in the study may last up to 3 months. the total duration of the study will be approximately 36 weeks.


Eligibility criteria:
inclusion criteria: * women aged 18 years or older of any race with an american society of anesthesiologists (asa) physical status of i to iii who are scheduled to undergo elective open abdominal surgery under general anesthesia. * women whose postoperative hospitalization is expected to last at least 24 hours * women expected to require postoperative intravenous opioid pca. * women whose surgery is expected to require at least 1 hour, but not more than 4 hours, of general anesthesia using the regimen defined in this protocol. * women of childbearing potential who have a negative pregnancy test or women who have been surgically sterilized or are postmenopausal. exclusion criteria: * women with clinically significant or unstable cardiac, respiratory, hepatic, renal, or other major organ system disease. * women with a known hypersensitivity to ondansetron (or any other 5-ht3 antagonist), to any agent that is part of the anesthesia regimen, or to other medications to be administered under this protocol. * women who are scheduled to undergo certain types of surgery. * women who are breastfeeding. * women who have retching/vomiting or moderate or severe nausea in the 24 hours prior to surgery or suffer from chronic nausea and/or vomiting. * women with a body mass index (bmi) \>40. * women who have participated in a clinical trial of an investigational drug within 30 days prior to drug administration.

Keywords: nausea vomiting
olfaction disorders in patients included in the trauma brain injury (tbi) database at trondheim university hospital

Conditions: Brain Injuries; Olfaction Disorders

Summary: the aim of the study is to see whether patients with chronic smell impairment after brain injury benefit from a treatment that consists of corticosteroids, and then olfactory training in 3 months.


Eligibility criteria:
inclusion criteria: * registered in the tbi database * 18-65 years of age per 01.10. 2012 * olfaction score by sniffin sticks threshold-discrimination-identification (tdi) \< 30 confirming dysosmia exclusion criteria: * unable to express senses. * unable to follow treatment and protocol * pregnancy * diabetes * tendency to infections * hypertonia * dyspepsia * interfering medication (hormonal treatment, nsaids, antidiabetics, barbiturates, fenitoin, carbamazepin, rifampicin, cyclophosphamides)

Keywords: olfactory perception adrenal cortex hormones steroids education
combination chemotherapy in treating patients with advanced hodgkin's disease

Conditions: Lymphoma

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. it is not yet known which chemotherapy regimen is more effective for advanced hodgkin's disease. purpose: randomized phase iii trial to compare different combination chemotherapy regimens in treating patients with advanced hodgkin's disease.

objectives: i. determine whether a four-drug anthracycline-based regimen or a seven-drug hybrid or eight-drug alternating regimen is the optimal treatment for patients with advanced hodgkin's disease. outline: this is a randomized study. patients are randomized to one of two treatment arms. arm i (abvd): patients receive doxorubicin iv, bleomycin iv, vinblastine iv, and dacarbazine iv on days 1 and 15. courses repeat every 4 weeks. arm ii (chlvpp/pabloe): patients receive oral chlorambucil, procarbazine, and prednisolone on days 1-14; vinblastine iv on days 1 and 8; doxorubicin iv on day 29; vincristine iv and bleomycin iv on days 29 and 36; oral etoposide on days 29-31; and oral prednisolone again on days 29-38. courses repeat every 7 weeks. or (hybrid - chlvpp/eva): patients receive vincristine iv on day 1; oral etoposide on days 1-5; oral chlorambucil, procarbazine, and prednisolone on days 1-7; and doxorubicin iv and vinblastine iv on day 8. courses repeat every 4 weeks. patients in both arms receive up to 6-8 courses of treatment. radiotherapy may be given to sites of previous bulk disease for patients in complete remission or uncertain remission. patients who achieve partial remission may receive radiotherapy to residual disease sites. patients who fail to respond, or have disease progression, may receive induction therapy followed by high-dose consolidation therapy. patients are followed every 3 months for 2 years, every 6 months for 5 years, and then annually for 5 years. projected accrual: approximately 800 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically confirmed advanced hodgkin's disease requiring systemic therapy stage ia or iia disease with bulky disease or more than three sites of involvement are also eligible patient characteristics: age: not specified performance status: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: no other active malignancy within 5 years hiv negative not pregnant or nursing fertile patients must use effective contraception prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy for hodgkin's disease endocrine therapy: not specified radiotherapy: no prior radiotherapy for hodgkin's disease surgery: not specified

Keywords: stage i adult hodgkin lymphoma stage ii adult hodgkin lymphoma stage iii adult hodgkin lymphoma stage iv adult hodgkin lymphoma
parkin mutations and their functional consequences

Conditions: Parkinson's Disease

Summary: parkinson's disease (pd) is the most frequent neurodegenerative disease with a prevalence of 2% over 65 years and because of this high prevalence as the population ages, it is a major problem of public health. an exhaustive repertory of not only parkin mutations in autosomal recessive forms of pd but also in other known genes such as dj-1, pink1 and lrrk2, is of major importance for both genetic counseling in families affected with pd and physiopathological approaches to this disease. through a french network for the study of parkinson's disease genetics and extended collaborations with european, mediterranean and other various countries, a total of 2934 subjects including 1683 patients and 1251 unaffected individuals has been collected since 2002. these samples consisted of 122 families with autosomal recessive pd, 285 cases of isolated early onset pd, 110 autosomal recessive and 129 autosomal dominant families with late onset pd, 201 isolated late onset pd cases and 250 matched controls. dnas from all subjects are now available, lymphocytes and lymphoblastoid cell lines have been stored for most patients from france and recently, fresh fibroblasts have been obtained for some individuals. the genetic approach to autosomal recessive pd is focused on the identification of mutations in the parkin gene but also on the screening of dj-1, pink1 and lrrk2 genes.


Eligibility criteria:
inclusion criteria: * patients presenting with parkinson's disease, with a family history or not, * minors presenting clinical signs of the disease, * controls (without signs of the disease, matched by sex and age with the patients, relatives for the familial cases) exclusion criteria: * persons refusing to sign the informed consent, * lack of clinical information

Keywords: parkinson's disease phenotype-genotype correlations mutations spectrum candidate genes
promoting wellbeing for women with depression: a pragmatic randomised controlled trial (rct) of an exercise programme

Conditions: Depression

Summary: the investigators want to find out if their specially designed exercise programme will be more successful at helping women with depression to feel better than a basic programme will, by measuring the effect the programme has on mood, physical health, and social wellbeing. their specially designed exercise programme will involve physical exertion at the participants' chosen level of intensity (how hard the body has to work during exercise), and will include motivational support. by contrast, the basic exercise programme will be at an intensity recommended by national guidelines, of the type that may be prescribed by a general practitioner (gp), and will include no extra motivational support.


Eligibility criteria:
inclusion criteria: * living with depression * aged 18 (age at first session of programme) * female * living in the community * resident within nottinghamshire (personal address has nottinghamshire postcode) exclusion criteria: * women who, at the time of the study, are unable to participate on account of any injury or physical health problem that precludes their participation * women participating in research that may undermine the scientific basis of the study

Keywords: depression mental health exercise prescribed exercise physical health social wellbeing
method and sample comparison study minicare bnp - comp-bnp-ce03-an2016

Conditions: Heart Failure

Summary: sample comparison the objective of this study is to compare the philips minicare bnp test with the centaur bnp test. bnp level measured in human blood samples (edta venous whole blood and/or edta plasma) will be assessed. matrix comparison to compare bnp measurements obtained using minicare system for edta whole blood and edta plasma samples.prior to the study start, a proficiency study will be performed on the minicare bnp, architect and i-stat bnp assay to be sure that devices are performing according to expectations. approximately 100 edta patient whole blood samples covering the entire measuring range of minicare bnp from loq until end of measuring range (expected to be approximately 5000 ng/l) (ref 7) will be tested (according to clsi ep09a3 (ref 5)) at a central laboratory using the minicare bnp, alere bnp, i-stat bnp system. the outcome of the site routine assay (centaur bnp systems) will be used to evaluate if the blood samples cover the entire distribution range of the assay. if necessary, up to 20% of the samples may be spiked so that the entire range of the assay is covered. the central laboratory will identify the blood tubes with a bnp request. approximately 1000 μl edta whole blood will be available (left over material) for testing on the non-routine devices (i.e., minicare bnp, alere bnp, and i-stat bnp). testing for the alere bnp, i-stat bnp, and centaur bnp systems will be performed according to the respective ifu's (ref 1, 2, 3, 4). for the minicare bnp system, test will be performed according to a draft ifu or a similar document describing the sample treatment and handling for the minicare bnp system. alere bnp, i-stat bnp and minicare bnp samples should be tested within 6 hours after collection and centaur bnp samples within 8h of collection. although different stability claims for bnp, it is highly recommended to perform all measurements on all systems within 2 hours. for alere bnp, i-stat bnp, centaur bnp analysis will be performed using a single blood sample for each patient. alere bnp and i-stat will use edta whole blood samples as sample type centaur bnp will be tested on edta plasma samples. for the minicare bnp, both edta whole blood and edta plasma will be tested for each patient. for the minicare bnp system the whole blood samples will be tested using a pipette and the same sample will be tested using the smearsafe blood dispenser (transfer device) to investigate a reliable use of such transfer device. only the routine centaur bnp outcomes will be used as part of support for patient diagnosis.


Eligibility criteria:
left over blood samples from eligible patients with bnp requests, available at the test site central laboratory will be selected for this study.

Keywords: ivd
fibrinogen as a surrogate for global haemostasis in plasma exchange

Conditions: Clotting Disorder Due to Plasma Exchange Therapy; Humoral Rejection After Kidney Transplantation

Summary: plasma exchange is a frequently used therapy in many antibody-mediated disorders, such as humoral rejection after kidney transplantation. treatment frequency is adjusted to daily measured fibrinogen blood levels to prevent bleeding complications. however, data about the correlation of fibrinogen blood levels and function of the coagulation system during plasma exchange therapy is scarce. in the present study we examine blood fibrinogen levels and coagulation factors as well as thrombin clotting time in patients under plasma exchange therapy.


Eligibility criteria:
inclusion criteria: * plasma exchange therapy due to humoral rejection after kidney transplantation exclusion criteria: * hereditary coagulopathy * chronic liver disease (child c) * therapeutic anticoagulation * malnutrition (bmi\<17.5)
exploring the correlation between post traumatic stress disorder, perceived stress and scar pruritus in burn patients

Conditions: Burns; Scar Pruritus; Post Traumatic Stress Disorder; Perceived Stress

Summary: pruritus, post traumatic stress disorder and perceived stress are common issues in burn patients. the correlation between the three is unclear so far. this study will collect data among adult patients with hypertrophic scars 21 days after the burn event has occurred. using a chinese version of the 5d itch scale,chinese version of the posttraumatic diagnostic scale and perceived stress scale to investigate self-reported postburn pruritus,post traumatic stress disorder and perceived stress. the patients will be wearing the smart watch for one month to collect data on their stress levels. this data will be used to analyze the correlation between posttraumatic stress syndrome, perceived stress and scar pruritus. there will be two rounds of data collection. the first will be when the smart watch is issued to patients, and the second will be at the end of the one month period.


Eligibility criteria:
inclusion criteria: * patients with hypertrophic scars 21 days after the burn event occurred * adult patients over 18 years old * patients without serious mental disorders, and are able to express themselves in chinese with clear consciousness. * the patient has no open wound on the wrist and is able to wear the smart watch continuously for one month exclusion criteria: * patients with first-degree burns * non-traumatic electrical burns
effect alveolar recruitment manoeuver on stroke volume a randomized study

Conditions: Alveolar Recruitment Manoeuver; Anesthesia

Summary: objective: to compare the effect of alveolar recruitment manouver through stepwise increase and decrease in airway pressure or sustained 30 secondes 30 cmh2o continuous positive airway pressure on cardiac stroke volume estimated by oesophageal doppler in preload independent anesthetized patients scheduled for surgery.

following anesthesia and preload optimisation guided by cardiac stroke volume, patients will be randomised to one alveolr recruitment manoeuver : * stepwise increase and decrease in positive airway pressure * sustained 30 secondes 30 cmh2o continuous positive airway pressure the primary objective is the change in cardiac stroke volume.

Eligibility criteria:
inclusion criteria: * adult patients scheduled for major surgery requiring hemodynamic monitoring * written signed informed consent exclusion criteria: * pregnancy * non sinusal heart rate * known cardiac right ventricular failure or arterial pulmonary hypertension * pneumothorax * known pulmonary emphysema
pms of spesolimab i.v. in gpp patients with acute symptoms

Conditions: Generalized Pustular Psoriasis

Summary: non-interventional cohort study in patients with newly initiated spesolimab to evaluate the incidence of adverse drug reactions and to understand generalized pustular psoriasis (gpp) disease activities in the real world setting.


Eligibility criteria:
inclusion criteria: * gpp patients with acute symptoms who are administered spesolimab intravenous (i.v.) infusion in japan * patients who have never been treated with spesolimab i.v. infusion before enrolment exclusion criteria: * none
does transcranial magnetic stimulation of the cingulate cortex modulate the perception of dyspnoea?

Conditions: Malignancy

Summary: the treatment we are studying is transcranial magnetic stimulation (tms). in tms, an electromagnetic pulse is passed into the brain through a coil placed on the head. previous studies have shown tms to be capable of altering brain activity in specific areas; for example it has been used to improve mood in clinical depression. in this study we will assess if, by targeting tms to the brain area responsible for feeling breathless, participants' breathlessness will be improved

this protocol describes an exploratory crossover pilot study to assess whether targeted repetitive pulse transcranial magnetic stimulation (tms) i.e. targeted at the anterior cingulate cortex (acc), affords relief of 'air hunger' in patients with breathlessness refractory to maximal medical therapy, compared to 'control' tms directed at a remote site independent of the area of interest (within the lateral right parietal region of the brain). 12 right-handed patients suffering from refractory dyspnoea will receive pulses of targeted tms or control tms (crossover design), in a random order. the order will be random and use a minimisation procedure for baseline dyspnoea severity and sex. repetitive targeted tms (or control) pulses at 110% motor threshold at a frequency of 1hz will be given for a 15 minute period1. on a second, later, day the same subjects will perform the same protocol after receiving inhaled menthol or control (normal, non odorous air), in random order. outcomes will be assessed during the 10 minutes after targeted tms/control tms during which post stimulation inhibition of neural activity is expected.

Eligibility criteria:
inclusion criteria: 1. refractory dyspnoea (persisting sensation of air hunger despite optimisation of medical treatment) 2. histocytologically proven thoracic malignancy 3. written informed consent exclusion criteria: 1. age \<18 years 2. left-handed 3. structural brain disease (including cerebral metastasis) 4. personal or family history of seizures 5. implantable metallic objects e.g. a pacemaker, or other contraindication to transcranial magnetic stimulation 6. pregnant or breast feeding 7. previous electroconvulsive therapy (ect) 8. poor mobility 9. visual impairment 10. lack of social support / home to go to after the study treatment 11. alcohol dependency 12. paco2 \>6kpa at rest 13. inability to provide informed consent

Keywords: histocytologically proven thoracic malignancy
coronal mode ultrasound guided hemodialysis cannulation: comparison with standard cannulation technique

Conditions: Arteriovenous Fistula, Cannulation

Summary: infiltrations from cannulation difficulties result in significant morbidity including loss of vascular access (va) loss in hemodialysis (hd). cannulation is reliant on personnel skill and va characteristics. surface marking of va lacks real-time information and traditional ultrasound (us) devices are large, expensive and require skilled operator expertise. sonic window© (analogic ultrasound, peabody, ma) is a coronal mode ultrasound device (cmud) approved for va cannulation. study is a single center randomized, prospective pilot study comparing handheld us-guided cannulation of new arteriovenous fistula (avf) to standard cannulation practices.


Eligibility criteria:
inclusion criteria: * end-stage renal disease with new arteriovenous fistula being started for cannulation exclusion criteria: * end-stage renal disease with grafts